London-based Stem Cell Sciences has agreed to sell its operating units and certain related assets to StemCells for about $715,000 in cash and 2.65 million shares of stock. The deal, which was cleared by both firms' boards of directors, covers stem cell technologies as well as expertise and infrastructure for cell-based assays used in treatment discovery and testing.

Related Summaries